Leqembi IQLIK injection training prepares patients and caregivers to give weekly treatment at home after in-person or virtual instruction. To prepare, families need confirmed eligibility, a refrigerator plan, and a schedule for safety MRIs. Leqembi IQLIK is a weekly under-the-skin form of lecanemab-irmb for early Alzheimer's disease. According to the FDA approval notice, FDA approved it on July 13, 2026 as an initiation dose of 500 mg weekly given as two back-to-back 250-mg autoinjector shots.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Can Start Home Injections?
- What Does Training Teach Caregivers?
- How Do You Give the Two Weekly Shots?
- How Do You Store and Travel With Autoinjectors?
- What Safety Checks Continue at Home?
Who Can Start Home Injections?
Treatment can start only in adults with mild cognitive impairment or mild dementia due to Alzheimer's. Amyloid-beta pathology must be confirmed before the first dose.
A recent baseline brain MRI is also required. This limits home treatment to biomarker-confirmed early-stage patients who can complete safety monitoring.
What Does Training Teach Caregivers?
Training focuses only on device use, not on deciding the dose. A Nurse Educator shows how to inspect the autoinjector, prepare the skin, hold the device in place, and confirm delivery. Each 250-mg injection takes about 15 seconds.
Patients or trained caregivers can give it at home without visiting an infusion center after training, according to FDA-approved labeling. Approved sites are the abdomen, thigh, or back of the upper arm when a caregiver gives the shot. Caregivers learn to rotate sites at least 1 inch from the prior shot and avoid the 2-inch area around the navel.
How Do You Give the Two Weekly Shots?
Let refrigerated autoinjectors warm about 20 minutes before use. Do not shake them, heat them another way, or return a warmed device to the refrigerator for later use.
Give two 250-mg shots in a row for one 500-mg weekly dose. Use a simple routine each week: Keep a weekly log with date, sites used, and any redness, swelling, or pain. Bring that log to each clinic visit.
- Check expiration, warm 20 minutes, wash hands, clean skin
- Give first 15-second shot in abdomen or thigh
- Choose a second site at least 1 inch away and give second 15-second shot
- Throw away single-use autoinjectors and record both shots
How Do You Store and Travel With Autoinjectors?
Store autoinjectors in the refrigerator at 2-8C, or 36-46F, in the original carton. The carton protects the medicine from light and keeps the pair together for the weekly dose. They may stay at room temperature up to 25C in the original carton for 14 days.
According to the Medication Guide, families need a storage and travel plan for that 14-day limit. For travel, carry the carton, plan refrigerator access at arrival, and count travel days toward the 14 days. Do not freeze the devices and do not use medicine left at room temperature past the limit.
What Safety Checks Continue at Home?
Home dosing does not remove brain-safety monitoring. Lecanemab carries a boxed warning for ARIA, meaning brain swelling or bleeding that often causes no symptoms. Patients need ApoE epsilon 4 testing before starting and MRIs after 1, 2, 3, and 6 months.
These scans look for silent changes that require a dose pause or stop. Call the prescribing team promptly for severe headache, confusion, dizziness, vision change, trouble walking, or weakness on one side. Keep the MRI schedule even when weekly shots feel routine.
You Might Also Like
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: Who May Qualify and Who Needs Further Review
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: Safety Warnings, Monitoring, and When to Call
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: Benefits, Limits, and Questions for the Prescriber
